1402821-41-3

GV-58 is a novel N- and P/Q-type calcium (Ca2+) channel agonist with EC50s of 7.21 and 8.81 μM, respectively. GV-58 slows the deactivation of channels, resulting in a large increase in presynaptic Ca2+ entry during activity. GV-58 can be used in lambert-eaton myasthenic syndrome (LEMS) research[1][2][3].

GV-58 is a roscovitine analog th at retains the ability to prolong the open state of calcium channelsbut unlike roscovitineis inactive against Cdk activity. GV-58 is a selective agonist of N-type and P/Q type calcium channelswhich are critical to the triggering of neurotransmitter release at the neuromuscular junction. GV-58 has been studied as a possible therapeutic agent in a mouse model of Lambert-Eaton myasthenic syndrome (LEMS). The EC50 values for activation of N-P/Q- and L- type calcium channels are 6.89.9 and >100 μMrespectively.

N-type calcium channel: 7.21 μM (EC₅₀); P/Q-type calcium?channel: 8.81 μM (EC₅₀)

+4°C

[1] Tarr TB, et al. Evaluation of a novel calcium channel agonist for therapeutic potential in Lambert-Eaton myasthenic syndrome. J Neurosci. 2013 Jun 19;33(25):10559-67. DOI:10.1523/JNEUROSCI.4629-12.2013
[2] Tarr TB, et al. Complete reversal of Lambert-Eaton myasthenic syndrome synaptic impairment by the combined use of a K+ channel blocker and a Ca2+ channel agonist. J Physiol. 2014 Aug 15;592(16):3687-96. DOI:10.1113/jphysiol.2014.276493
[3] Meriney SD, et al. Lambert-Eaton myasthenic syndrome: mouse passive-transfer model illuminates disease pathology and facilitates testing therapeutic leads. Ann N Y Acad Sci. 2018 Jan;1412(1):73-81. DOI:10.1111/nyas.13512